Last reviewed · How we verify
Carlos A Acosta-Olivo — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Tranexamic acid tablets | Tranexamic acid tablets | phase 3 | Antifibrinolytic agent | Plasminogen / Plasmin | Hematology / Hemostasis |
Therapeutic area mix
- Hematology / Hemostasis · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Chinese Academy of Medical Sciences, Fuwai Hospital · 1 shared drug class
- Dr. Lutfi Kirdar Kartal Training and Research Hospital · 1 shared drug class
- Hamilton Health Sciences Corporation · 1 shared drug class
- Henry Ford Health System · 1 shared drug class
- Massachusetts General Hospital · 1 shared drug class
- Montefiore Medical Center · 1 shared drug class
- Mount Sinai Hospital, Canada · 1 shared drug class
- Aswan University Hospital · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Carlos A Acosta-Olivo:
- Carlos A Acosta-Olivo pipeline updates — RSS
- Carlos A Acosta-Olivo pipeline updates — Atom
- Carlos A Acosta-Olivo pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Carlos A Acosta-Olivo — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/carlos-a-acosta-olivo. Accessed 2026-05-17.